DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
« Back to Dashboard
Summary for Patent: 5,589,331
|Title:||Method for detecting abnormal serotonergic function|
|Abstract:||A method of detecting abnormal serotonergic function in an impulsive human subject is disclosed. The method comprises detecting an L allele of a gene encoding tryptophan hydroxylase. The invention also includes an isolated nucleic acid having a sequence specific to an L allele of a gene encoding tryptophan hydroxylase. The nucleic acid may migrate in a denaturing gel at the same rate as a second nucleic acid specific to a corresponding region of a U allele of a gene encoding tryptophan hydroxylase, and migrate in a nondenaturing gel at a rate about 1.02 times the migration rate of the second nucleic acid.|
|Inventor(s):||Nielsen; David A. (Kensington, MD), Goldman; David (Potomac, MD), Linnoila; Markku (Bethesda, MD), Virkkunen; Matti (Helsinki, FI)|
|Assignee:||The United States of America as represented by the Department of Health (Washington, DC)|
|Patent Claims:||1. A method of detecting abnormal serotonergic function in an impulsive human subject, the method comprising:
providing a nucleic acid sample from the human subject;
detecting the presence or absence of an L allele of the gene encoding tryptophan hydroxylase in the sample, wherein detecting the presence of the L allele detects abnormal serotonergic function in the impulsive human subject.
2. The method of claim 1, wherein the L allele is in a homozygous state.
3. The method of claim 1 wherein the L allele is detected using a polymerase chain reaction.
4. The method of claim 3 wherein the polymerase chain reaction uses primers that hybridize to the same nucleic acid sequence as an oligonucleotide selected from the group that consists of:
HTHSSCP4: 5'-TTCAGATCCCTTCTATACCCCAGAG-3' (Seq. ID No.:3)
HTHSSCP5: 5'-GGACATGACCTAAGAGTTCATGGCA-3' (Seq. ID No.:4).
5. The method of claim 1 wherein the L allele is detected by single strand conformation polymorphism analysis.
6. The method of claim 1 wherein the L allele is associated with a polymorphism within an intron of the gene encoding tryptophan hydroxylase.
7. The method of claim 6 wherein the intron corresponds to intron 7 of the mouse gene encoding tryptophan hydroxylase.
8. The method of claim 1 wherein the abnormal serotonergic function is suicidal behavior.
9. The method of claim 7 wherein the polymorphism is correlated with suicidal behavior.
10. An isolated nucleic acid consisting of a subsequence of the L allele of the gene encoding tryptophan hydroxylase, wherein the subsequence is SEQ. ID No:8.
11. The nucleic acid of claim 10 wherein the nucleic acid is obtained by polymerase chain reaction amplification of a nucleic acid sample from an impulsive subject.
12. A nucleic acid of claim 10 wherein the subsequence of the L allele comprises an intron.
13. A nucleic acid of claim 12 wherein the intron corresponds to intron 7 of the mouse gene encoding tryptophan hydroxylase.
|Applicant||Tradename||Biologic Ingredient||Dosage Form||BLA||Number||Approval Date||Patent No.||Assignee||Estimated Patent Expiration||Status||Orphan||Source|
|Schering||INTRON A||interferon alfa-2b||VIAL||103132||001||1986-06-04||⤷ Free Forever Trial||The United States of America as represented by the Department of Health (Washington, DC)||2013-12-31||RX||search|
|Schering||INTRON A||interferon alfa-2b||VIAL||103132||002||1986-06-04||⤷ Free Forever Trial||The United States of America as represented by the Department of Health (Washington, DC)||2013-12-31||RX||search|
|Schering||INTRON A||interferon alfa-2b||VIAL||103132||003||1986-06-04||⤷ Free Forever Trial||The United States of America as represented by the Department of Health (Washington, DC)||2013-12-31||RX||search|
|>Applicant||>Tradename||>Biologic Ingredient||>Dosage Form||>BLA||>Number||>Approval Date||>Patent No.||>Assignee||>Estimated Patent Expiration||>Status||>Orphan||>Source|
|Country||Patent Number||Estimated Expiration|
|Australia||4033793||⤷ Free Forever Trial|
|Australia||682002||⤷ Free Forever Trial|
|Canada||2130904||⤷ Free Forever Trial|
|European Patent Office||0637341||⤷ Free Forever Trial|
|Japan||H07507206||⤷ Free Forever Trial|
|World Intellectual Property Organization (WIPO)||9322458||⤷ Free Forever Trial|
|>Country||>Patent Number||>Estimated Expiration|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.